Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28985671)

Published in Clin Infect Dis on August 01, 2017

Authors

Brian N Tse1, Amesh A Adalja2,3, Christopher Houchens1, Joseph Larsen1, Thomas V Inglesby2, Richard Hatchett4

Author Affiliations

1: Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), US Department of Health and Human Services (US DHHS), Washington, District of Columbia.
2: Center for Health Security, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
3: Division of Infectious Disease, University of Pittsburgh School of Medicine, Pennsylvania.
4: BARDA, ASPR, US DHHS, Washington, District of Columbia.

Articles cited by this

Bacteriophage resistance mechanisms. Nat Rev Microbiol (2010) 7.38

The biology and future prospects of antivirulence therapies. Nat Rev Microbiol (2008) 3.83

Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol (2014) 1.64

Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol (2014) 1.47

Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis (2016) 1.37

Diet-microbiota interactions as moderators of human metabolism. Nature (2016) 1.31

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. J Infect Dis (2016) 1.22

A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother (2014) 1.13

Interactions between the microbiota and pathogenic bacteria in the gut. Nature (2016) 0.99

Synthetic antibiofilm peptides. Biochim Biophys Acta (2015) 0.90

Novel pentadecenyl tetrazole enhances susceptibility of methicillin-resistant Staphylococcus aureus biofilms to gentamicin. Antimicrob Agents Chemother (2011) 0.87

Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep (2016) 0.83

Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med (2016) 0.83

Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review. Open Forum Infect Dis (2016) 0.82

Design, synthesis and biological evaluation of novel hamamelitannin analogues as potentiators for vancomycin in the treatment of biofilm related Staphylococcus aureus infections. Bioorg Med Chem (2016) 0.81

Synergistic Antipseudomonal Effects of Synthetic Peptide AMP38 and Carbapenems. Molecules (2016) 0.80

A macrophage-stimulating compound from a screen of microbial natural products. J Antibiot (Tokyo) (2014) 0.79

Impact of Azithromycin on the Quorum Sensing-Controlled Proteome of Pseudomonas aeruginosa. PLoS One (2016) 0.79

Antisense antimicrobial therapeutics. Curr Opin Microbiol (2016) 0.79

An anti-infective synthetic peptide with dual antimicrobial and immunomodulatory activities. Sci Rep (2016) 0.78